Literature DB >> 11151904

Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.

V K Sharma1, F A Corder, J Fancher, C W Howden.   

Abstract

OBJECTIVES: Primary care physicians and internal medicine residents have poor understanding of colorectal cancer screening and the use of fecal occult blood tests. If acceptance and implementation of colorectal cancer screening is to improve, gastroenterologists may have to take a more leading role in the education of their primary care colleagues, physicians in training, and the general public. However, before this can be recommended, it is necessary to determine how closely gastroenterologists follow currently recommended guidelines and how they use fecal occult blood tests.
METHODS: We mailed a two-page, structured questionnaire about colorectal cancer screening and use of fecal occult blood tests to 8000 randomly selected gastroenterologists in the United States.
RESULTS: We received responses from 24% of the gastroenterologists. Almost all used fecal occult blood tests in the office setting, 86% on stool obtained at rectal examination. The test was frequently used for reasons other than colorectal cancer screening, and often without adequate patient instruction on dietary and medication restrictions. Of the respondents, 98% commenced screening at age < or = 50 yr, whereas 37% either continued screening into advanced age or never stopped. Annual fecal occult blood testing with flexible sigmoidoscopy every 5 yr was the screening strategy recommended by 71% of the respondents, whereas 25% recommended colonoscopy every 10 yr. However, 77% of the gastroenterologists chose colonoscopy for personal colorectal cancer screening.
CONCLUSIONS: Gastroenterologists usually give appropriate advice on colorectal cancer screening but often misuse fecal occult blood tests. This may produce excessively high false-positive screening rates, leading to unnecessary diagnostic testing without apparent benefit.

Entities:  

Mesh:

Year:  2000        PMID: 11151904     DOI: 10.1111/j.1572-0241.2000.03381.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  Colorectal cancer screening perceptions and practices: results from a national survey of gastroenterology, surgery and radiology trainees.

Authors:  Amy S Oxentenko; Robert A Vierkant; Darrell S Pardi; David R Farley; Eric J Dozois; Thomas E Hartman; David M Hough; Wesley O Petersen; Carrie N Klabunde; Katherine Sharpe; John H Bond; Robert A Smith; Bernard Levin; John B Pope; Paul C Schroy; Paul J Limburg
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

2.  Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists.

Authors:  Meaghan Donovan; Kevin Lunney; Olivia Carter-Pokras; Raymond K Cross
Journal:  Dig Dis Sci       Date:  2007-04-07       Impact factor: 3.199

3.  Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin.

Authors:  Lulu Iles-Shih; Judy F Collins; Jennifer L Holub; David A Lieberman
Journal:  Am J Gastroenterol       Date:  2010-08-03       Impact factor: 10.864

Review 4.  Are medication restrictions before FOBT necessary?: practical advice based on a systematic review of the literature.

Authors:  Gerald Konrad; Alan Katz
Journal:  Can Fam Physician       Date:  2012-09       Impact factor: 3.275

5.  Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review.

Authors:  Neeraj Narula; Diana Ulic; Raed Al-Dabbagh; Ali Ibrahim; Maged Mansour; Cynthia Balion; John K Marshall
Journal:  Can J Gastroenterol Hepatol       Date:  2014-07-11

6.  Use of fecal occult blood test in hospitalized patients: survey of physicians practicing in a large central Canadian health region and Canadian gastroenterologists.

Authors:  Stephen Ip; AbdulRazaq A H Sokoro; Al Buchel; Debrah Wirtzfeld; Gerald Konrad; Tunji Fatoye; Harminder Singh
Journal:  Can J Gastroenterol       Date:  2013-12       Impact factor: 3.522

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.